Semaglutide vs. Sitagliptin: Efficacy and Safety in Japanese Type 2 Diabetes

Type 2 Diabetes is a chronic metabolic condition characterized by high blood sugar levels, affecting millions worldwide. Effective management is crucial to prevent severe complications, often involving medications like GLP-1 receptor agonists (e.g., semaglutide) and DPP-4 inhibitors (e.g., sitagliptin), which improve glycemic control through distinct mechanisms. This study addresses the knowledge gap by providing a direct comparison of once-weekly semaglutide monotherapy against once-daily sitagliptin monotherapy in a Japanese population with Type 2 Diabetes.